Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer.
10.3346/jkms.2007.22.S.S115
- Author:
Keun Wook LEE
1
;
Jee Hyun KIM
;
Tak YUN
;
Eun Kee SONG
;
Im Il NA
;
Hyunchoon SHIN
;
So Yeon OH
;
In Sil CHOI
;
Do Youn OH
;
Dong Wan KIM
;
Seock Ah IM
;
Tae You KIM
;
Jong Seok LEE
;
Dae Seog HEO
;
Yung Jue BANG
;
Noe Kyeong KIM
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. jhkimmd@snu.ac.kr
- Publication Type:Original Article ; Clinical Trial, Phase II ; Research Support, Non-U.S. Gov't
- Keywords:
Chemotherapy;
Paclitaxel;
Cisplatin, Gastric Cancer
- MeSH:
Adenocarcinoma/*drug therapy;
Adult;
Aged;
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse;
Cisplatin/administration & dosage/adverse effects;
Female;
Fluorouracil/administration & dosage/adverse effects;
Humans;
Leucovorin/administration & dosage/adverse effects;
Male;
Middle Aged;
Organoplatinum Compounds/administration & dosage/adverse effects;
Paclitaxel/administration & dosage/adverse effects;
Stomach Neoplasms/*drug therapy/mortality;
Survival Rate;
Treatment Failure
- From:Journal of Korean Medical Science
2007;22(Suppl):S115-S121
- CountryRepublic of Korea
- Language:English
-
Abstract:
This study was performed to evaluate the efficacy and toxicity of low-dose paclitaxel/cisplatin chemotherapy in patients with metastatic or recurrent gastric cancer that had failed 5-fluorouracil/platinum-based chemotherapy. Thirty-two patients with documented progression on or within 6 months after discontinuing 5-fluorouracil/platinum-based chemotherapy were enrolled. As a second-line treatment, paclitaxel (145 mg/m2) and cisplatin (60 mg/m2) was administered on day 1 every 3 weeks. Among 32 patients enrolled, 8 (25%) responded partially to paclitaxel/cisplatin, 8 (25%) had stable disease, and 14 (44%) had progressive disease. Two patients (6%) were not evaluable. The median time to progression (TTP) and overall survival for all patients were 2.9 months and 9.1 months, respectively. The most common hematologic toxicity was anemia (47%). Grade 3 neutropenia developed in three patients (9%), but no other grade 3/4 hematologic toxicity occurred. The most common non-hematologic toxicities were emesis (31%) and peripheral neuropathy (38%). Three cases (9%) of grade 3/4 emesis and 2 cases (6%) of grade 3 peripheral neuropathy developed. In conclusion, low-dose paclitaxel and cisplatin chemotherapy showed moderate activity with favorable toxicity profiles. However, relatively short TTP of this regimen warrants the development of more effective paclitaxel-based regimens other than combination with cisplatin in these patients as second-line therapies.
